tetano
Editor, Senior Moderator
PLoS Med
. 2023 Dec 7;20(12):e1004317.
doi: 10.1371/journal.pmed.1004317. Online ahead of print. Intensified screening for SARS-CoV-2 in 18 emergency departments in the Paris metropolitan area, France (DEPIST-COVID): A cluster-randomized, two-period, crossover trial
Judith Leblanc[SUP] 1 [/SUP], Lisbeth Dusserre-Telmon[SUP] 2 [/SUP], Anthony Chauvin[SUP] 3 [/SUP], Tabassome Simon[SUP] 4 [/SUP], Chiara E Sabbatini[SUP] 5 [/SUP], Karla Hemming[SUP] 6 [/SUP], Vittoria Colizza[SUP] 5 [/SUP], Laurence Bérard[SUP] 7 [/SUP], Jérome Convert[SUP] 8 [/SUP], Sonia Lazazga[SUP] 9 [/SUP], Carole Jegou[SUP] 10 [/SUP], Nabila Taibi[SUP] 11 [/SUP], Sandrine Dautheville[SUP] 12 [/SUP], Damien Zaghia[SUP] 13 [/SUP], Camille Gerlier[SUP] 14 [/SUP], Muriel Domergue[SUP] 15 [/SUP], Florine Larrouturou[SUP] 16 [/SUP], Florence Bonnet[SUP] 17 [/SUP], Arnaud Fontanet[SUP] 18 [/SUP], Sarah Salhi[SUP] 7 [/SUP], Jérome LeGoff[SUP] 19 [/SUP], Anne-Claude Crémieux[SUP] 20 [/SUP]; DEPIST-COVID group; FHU IMPEC (Improving Emergency Care) group
Affiliations
Background: Asymptomatic and paucisymptomatic infections account for a substantial portion of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmissions. The value of intensified screening strategies, especially in emergency departments (EDs), in reaching asymptomatic and paucisymptomatic patients and helping to improve detection and reduce transmission has not been documented. The objective of this study was to evaluate in EDs whether an intensified SARS-CoV-2 screening strategy combining nurse-driven screening for asymptomatic/paucisymptomatic patients with routine practice (intervention) could contribute to higher detection of SARS-CoV-2 infections compared to routine practice alone, including screening for symptomatic or hospitalized patients (control).
Methods and findings: We conducted a cluster-randomized, two-period, crossover trial from February 2021 to June 2021 in 18 EDs in the Paris metropolitan area, France. All adults visiting the EDs were eligible. At the start of the first period, 18 EDs were randomized to the intervention or control strategy by balanced block randomization with stratification, with the alternative condition being applied in the second period. During the control period, routine screening for SARS-CoV-2 included screening for symptomatic or hospitalized patients. During the intervention period, in addition to routine screening practice, a questionnaire about risk exposure and symptoms and a SARS-CoV-2 screening test were offered by nurses to all remaining asymptomatic/paucisymptomatic patients. The primary outcome was the proportion of newly diagnosed SARS-CoV-2-positive patients among all adults visiting the 18 EDs. Primary analysis was by intention-to-treat. The primary outcome was analyzed using a generalized linear mixed model (Poisson distribution) with the center and center by period as random effects and the strategy (intervention versus control) and period (modeled as a weekly categorical variable) as fixed effects with additional adjustment for community incidence. During the intervention and control periods, 69,248 patients and 69,104 patients, respectively, were included for a total of 138,352 patients. Patients had a median age of 45.0 years [31.0, 63.0], and women represented 45.7% of the patients. During the intervention period, 6,332 asymptomatic/paucisymptomatic patients completed the questionnaire; 4,283 were screened for SARS-CoV-2 by nurses, leading to 224 new SARS-CoV-2 diagnoses. A total of 1,859 patients versus 2,084 patients were newly diagnosed during the intervention and control periods, respectively (adjusted analysis: 26.7/1,000 versus 26.2/1,000, adjusted relative risk: 1.02 (95% confidence interval (CI) [0.94, 1.11]; p = 0.634)). The main limitation of this study is that it was conducted in a rapidly evolving epidemiological context.
Conclusions: The results of this study showed that intensified screening for SARS-CoV-2 in EDs was unlikely to identify a higher proportion of newly diagnosed patients.
Trial registration: Trial registration number: ClinicalTrials.gov NCT04756609.
. 2023 Dec 7;20(12):e1004317.
doi: 10.1371/journal.pmed.1004317. Online ahead of print. Intensified screening for SARS-CoV-2 in 18 emergency departments in the Paris metropolitan area, France (DEPIST-COVID): A cluster-randomized, two-period, crossover trial
Judith Leblanc[SUP] 1 [/SUP], Lisbeth Dusserre-Telmon[SUP] 2 [/SUP], Anthony Chauvin[SUP] 3 [/SUP], Tabassome Simon[SUP] 4 [/SUP], Chiara E Sabbatini[SUP] 5 [/SUP], Karla Hemming[SUP] 6 [/SUP], Vittoria Colizza[SUP] 5 [/SUP], Laurence Bérard[SUP] 7 [/SUP], Jérome Convert[SUP] 8 [/SUP], Sonia Lazazga[SUP] 9 [/SUP], Carole Jegou[SUP] 10 [/SUP], Nabila Taibi[SUP] 11 [/SUP], Sandrine Dautheville[SUP] 12 [/SUP], Damien Zaghia[SUP] 13 [/SUP], Camille Gerlier[SUP] 14 [/SUP], Muriel Domergue[SUP] 15 [/SUP], Florine Larrouturou[SUP] 16 [/SUP], Florence Bonnet[SUP] 17 [/SUP], Arnaud Fontanet[SUP] 18 [/SUP], Sarah Salhi[SUP] 7 [/SUP], Jérome LeGoff[SUP] 19 [/SUP], Anne-Claude Crémieux[SUP] 20 [/SUP]; DEPIST-COVID group; FHU IMPEC (Improving Emergency Care) group
Affiliations
- PMID: 38060611
- DOI: 10.1371/journal.pmed.1004317
Background: Asymptomatic and paucisymptomatic infections account for a substantial portion of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmissions. The value of intensified screening strategies, especially in emergency departments (EDs), in reaching asymptomatic and paucisymptomatic patients and helping to improve detection and reduce transmission has not been documented. The objective of this study was to evaluate in EDs whether an intensified SARS-CoV-2 screening strategy combining nurse-driven screening for asymptomatic/paucisymptomatic patients with routine practice (intervention) could contribute to higher detection of SARS-CoV-2 infections compared to routine practice alone, including screening for symptomatic or hospitalized patients (control).
Methods and findings: We conducted a cluster-randomized, two-period, crossover trial from February 2021 to June 2021 in 18 EDs in the Paris metropolitan area, France. All adults visiting the EDs were eligible. At the start of the first period, 18 EDs were randomized to the intervention or control strategy by balanced block randomization with stratification, with the alternative condition being applied in the second period. During the control period, routine screening for SARS-CoV-2 included screening for symptomatic or hospitalized patients. During the intervention period, in addition to routine screening practice, a questionnaire about risk exposure and symptoms and a SARS-CoV-2 screening test were offered by nurses to all remaining asymptomatic/paucisymptomatic patients. The primary outcome was the proportion of newly diagnosed SARS-CoV-2-positive patients among all adults visiting the 18 EDs. Primary analysis was by intention-to-treat. The primary outcome was analyzed using a generalized linear mixed model (Poisson distribution) with the center and center by period as random effects and the strategy (intervention versus control) and period (modeled as a weekly categorical variable) as fixed effects with additional adjustment for community incidence. During the intervention and control periods, 69,248 patients and 69,104 patients, respectively, were included for a total of 138,352 patients. Patients had a median age of 45.0 years [31.0, 63.0], and women represented 45.7% of the patients. During the intervention period, 6,332 asymptomatic/paucisymptomatic patients completed the questionnaire; 4,283 were screened for SARS-CoV-2 by nurses, leading to 224 new SARS-CoV-2 diagnoses. A total of 1,859 patients versus 2,084 patients were newly diagnosed during the intervention and control periods, respectively (adjusted analysis: 26.7/1,000 versus 26.2/1,000, adjusted relative risk: 1.02 (95% confidence interval (CI) [0.94, 1.11]; p = 0.634)). The main limitation of this study is that it was conducted in a rapidly evolving epidemiological context.
Conclusions: The results of this study showed that intensified screening for SARS-CoV-2 in EDs was unlikely to identify a higher proportion of newly diagnosed patients.
Trial registration: Trial registration number: ClinicalTrials.gov NCT04756609.